Engineering Primary T cells for Resistance to HIV-1

改造原代 T 细胞以抵抗 HIV-1

基本信息

  • 批准号:
    7405372
  • 负责人:
  • 金额:
    $ 4.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-09-01 至 2008-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This research application focuses on the generation of HIV-1 resistant primary T cells as potential translational immunotherapies for HIV-1. The specific aims include: 1) engineering primary T cells with a membrane bound form of the HIV-1 fusion inhibitor C34, evaluation of antiviral effects and cellular immune function, 2) development of strategies to compare and combine multi-target transgenes in a lentiviral backbone vector and 3) investigation of the immunogenicity of HIV epitopes exposed as a result of binding to the fusion inhibitor expressed on the target cell. A self-inactivating lentiviral vector system will be used to deliver genes coding for membrane bound forms of an HIV-1 entry inhibitor alone, and in combination with small interfering RNAs against HIV-1 co-receptor CCR5, and HIV genes Rev and Tat. Transduced primary T cells will be challenged with a variety of HIV-1 viruses including primary isolates, and cells will be evaluated for immunologic function. Preliminary studies in primary T cells are promising for the membrane bound entry inhibitor, and we hypothesize that combinations with siRNA against viral co-receptor and/or regulatory HIV genes will have an additive anti-viral effect. This proposal describes a 5-year training program for the development of an academic career in Pediatric Allergy and Immunology (A/I). The principal investigator has completed Pediatric residency training at the Children's Hospital of Philadelphia, and is in her third year of A/I Fellowship. This grant will allow the investigator to broaden her scientific skills while benefiting from the diverse resources available at the University of Pennsylvania (UPENN) within the Department of Immunology, the Center for AIDS Research (CFAR), and the Abramson Family Cancer Research Institute (AFCRI). Drs. Carl June and James Hoxie will mentor Dr. Perez's scientific career development. Dr. June is the Director of the Translational Research Program of the AFCRI, and has led pioneering translational research in T cell biology and adoptive immunotherapy of cancer and HIV infection. Dr. Hoxie, Director of the UPENN CFAR, has an extensive background in HIV virology, pathogenesis and viral entry.
描述(由申请人提供):本研究申请的重点是产生HIV-1抗性原代T细胞,作为HIV-1的潜在翻译免疫疗法。具体目标包括:1)用膜结合形式的HIV-1融合抑制剂C34改造原代T细胞,评价抗病毒作用和细胞免疫功能,2)开发在慢病毒骨架载体中比较和联合收割机组合多靶转基因的策略,和3)研究由于与靶细胞上表达的融合抑制剂结合而暴露的HIV表位的免疫原性。自失活慢病毒载体系统将用于单独递送编码膜结合形式的HIV-1进入抑制剂的基因,以及与针对HIV-1共受体CCR 5的小干扰RNA和HIV基因Rev和达特的组合。转导的原代T细胞将用各种HIV-1病毒(包括原代分离株)进行攻击,并评价细胞的免疫功能。在原代T细胞中的初步研究对于膜结合进入抑制剂是有希望的,并且我们假设与针对病毒共受体和/或调节HIV基因的siRNA的组合将具有附加的抗病毒作用。该提案描述了一个为期5年的培训计划,用于发展儿科过敏和免疫学(A/I)的学术生涯。主要研究者已在费城儿童医院完成儿科住院医师培训,并在她的A/I奖学金的第三年。该补助金将使研究人员能够扩大她的科学技能,同时受益于宾夕法尼亚大学(UPENN)免疫学系,艾滋病研究中心(CFAR)和Abramson家庭癌症研究所(AFCRI)的各种资源。卡尔·琼博士和詹姆斯·霍克西博士将指导佩雷斯博士的科学职业发展。June博士是AFCRI转化研究项目的主任,领导了T细胞生物学和癌症和HIV感染的过继免疫疗法的开创性转化研究。Hoxie博士是宾夕法尼亚大学CFAR主任,在艾滋病毒病毒学、发病机制和病毒进入方面有着广泛的背景。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ELENA E PEREZ其他文献

ELENA E PEREZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ELENA E PEREZ', 18)}}的其他基金

Uncovering co-stimulatory T cell help defects in common variable immunodeficiency
发现共刺激 T 细胞有助于常见变异免疫缺陷的缺陷
  • 批准号:
    7939826
  • 财政年份:
    2009
  • 资助金额:
    $ 4.05万
  • 项目类别:
Uncovering co-stimulatory T cell help defects in common variable immunodeficiency
发现共刺激 T 细胞有助于常见变异免疫缺陷的缺陷
  • 批准号:
    7707543
  • 财政年份:
    2009
  • 资助金额:
    $ 4.05万
  • 项目类别:
Engineering Primary T cells for Resistance to HIV-1
改造原代 T 细胞以抵抗 HIV-1
  • 批准号:
    6937212
  • 财政年份:
    2004
  • 资助金额:
    $ 4.05万
  • 项目类别:
Engineering Primary T cells for Resistance to HIV-1
改造原代 T 细胞以抵抗 HIV-1
  • 批准号:
    7761390
  • 财政年份:
    2004
  • 资助金额:
    $ 4.05万
  • 项目类别:
Engineering Primary T cells for Resistance to HIV-1
改造原代 T 细胞以抵抗 HIV-1
  • 批准号:
    7058743
  • 财政年份:
    2004
  • 资助金额:
    $ 4.05万
  • 项目类别:
Engineering Primary T cells for Resistance to HIV-1
改造原代 T 细胞以抵抗 HIV-1
  • 批准号:
    6843528
  • 财政年份:
    2004
  • 资助金额:
    $ 4.05万
  • 项目类别:
Engineering Primary T cells for Resistance to HIV-1
改造原代 T 细胞以抵抗 HIV-1
  • 批准号:
    7225947
  • 财政年份:
    2004
  • 资助金额:
    $ 4.05万
  • 项目类别:
MINORITY PREDOCTORAL FELLOWSHIP PROGRAM--NIGMS
少数族裔博士前奖学金计划
  • 批准号:
    2328923
  • 财政年份:
    1995
  • 资助金额:
    $ 4.05万
  • 项目类别:
MINORITY PREDOCTORAL FELLOWSHIP PROGRAM--NIGMS
少数族裔博士前奖学金计划
  • 批准号:
    2169464
  • 财政年份:
    1995
  • 资助金额:
    $ 4.05万
  • 项目类别:
MINORITY PREDOCTORAL FELLOWSHIP PROGRAM--NIGMS
少数族裔博士前奖学金计划
  • 批准号:
    2169463
  • 财政年份:
    1994
  • 资助金额:
    $ 4.05万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 4.05万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 4.05万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.05万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.05万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 4.05万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.05万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 4.05万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 4.05万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 4.05万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.05万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了